MNPHARN’s merger with Zoltan Labs is Complete:
For the past few years we have been working with Zoltan Labs, to express a human recombinant regenerative protein known as PLAP (Placental Alkaline Phosphatase). Until this merger, Zoltan Labs was the holder of many patents for the use of PLAP.

After MNPHARM successfully expressed PLAP at 1/10th the cost of traditional methods, it made sense to merge the two companies.

MNPHARM now produces PLAP at a lower cost than anyone in the world, and holds 19 patents for the use of PLAP.

Among other Patented attributes, PLAP Promotes the Generation of Skin Cells, which can be used to Treat Acne Vulgaris, Melanoma, Scaring, Burn Victim’s, Skin Mesh Dressings, Plaque Psoriasis, Nail Infections, Infections of Non-Healing Diabetic Wounds, Puncture Wounds, Surgical Wounds and Incisions, Abrasions, Lacerations, Ulcers, Gum Disease, Skin Tears, Wounds Caused by Bites or Stings to name a few.

PLAP is also Patented for Chronic Wasting from Cancer Treatment, Prevent the Loss of Skeletal Muscle Proteins During Cancer Treatment, Enhance Viability of Stem Cells, Promotes the Formation of Blood Cells and more.